



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




JDQ443

Item No. 38157

CAS Registry No.: 2653994-08-0
Formal Name: 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one

Synonym: Opnurasib
MF: C₂₉H₂₈ClN₇O
FW: 526.0
Purity: ≥98%
UV/Vis.: λ_{max}: 242 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JDQ443 is supplied as a solid. A stock solution may be made by dissolving the JDQ443 in the solvent of choice, which should be purged with an inert gas. JDQ443 is soluble in the organic solvent DMSO.

Description

JDQ443 is a covalent inhibitor of K-Ras^{G12C}, a mutant form of K-Ras that accumulates in cancer cells.¹ It decreases K-Ras^{G12C}-induced phosphorylation of ERK in NCI H358 non-small cell lung cancer (NSCLC) cells (IC₅₀ = 0.020 μM). JDQ443 selectively inhibits the growth of NCI H358 cells, which express K-Ras^{G12C}, over NCI H1437 NSCLC cells expressing wild-type K-Ras and the constitutively active mutant MEK^{Q56P} (GI₅₀s = 0.018 and 4.4 μM, respectively). It reduces blood levels of free K-Ras^{G12C} at three, six, and 24 hours in a MiaPaCa-2 pancreatic cancer mouse xenograft model when administered at a dose of 30 mg/kg and inhibits tumor growth and decreases tumor volume in the same model at 10 and 30 mg/kg per day.

Reference

1. Lorthiois, E., Gerspacher, M., Beyer, K.S., *et al.* JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS^{G12C} for the treatment of solid tumors. *J. Med. Chem.* **65(24)**, 16173-16203 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/18/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM